Of translational interest, targeting ETAR activity in ovarian cancer cells and xenografts, by using the FDA approved small molecule macitentan, results in the inhibition of invasive behavior and metastatic progression with the concomitant reduction of ZEB1 and the increase of miR-200b/c expression, validating the existence of the integrated ETAR-miR-200b/c-ZEB1 circuit in metastatic nodules. The gene discussed is ZEB1; the disease is ovarian carcinoma.